An Explosive 2024 Is Ending This Bio-Tech To New Heights! ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
A message from Sideways Frequency
BSEM Has Announced Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million! 2024 has been a record year in revenues for rising biotech firm BioStem Technologies Inc. (OTC: BSEM). The company recently revealed preliminary results that show Q4 net revenue expecting to be $102.9M. This is a whopping 794% increase over Q4 in 2023! Full year net revenue for 2024 is anticipated to be $301.8M, representinga stellar 1,702% growth since fiscal year 2023!This growth is nothing short of incredible and only showcases the exciting growth potential for BSEM, a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care. The company is addressing two multi-billion-dollar markets and has been releasing steady positive developments. This includes starting off 2025 by launching a new clinical trial!
Zack’s Small Cap Research has been bullish on the company with several price target updates in the last year. Most recently after Q3 results were announced, Zack’s upped its price target on BSEM to $32.50! Could another target price hike be on the way? AND ON ANOTHER EXCITING FRONT THAT COULD SERVE AS A CATALYST FOR GROWTH IS THAT A NASDAQ LISTING COULD BE AROUND THE CORNER FOR THE COMPANY! BSEM announced not long ago that it has filed with the SEC to register its shares pursuant to the Securities Exchange Act of 1934, which is an important step in its plan to uplist to the Nasdaq stock exchange. See why BSEM continues to blow revenues out of the water and why a listing on the NASDAQ could mean more exponential growth ahead! This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $5,200 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between January 15, 2025 and January 21, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
|
|
|
